Related Experiment Videos
Piribedil for restless legs syndrome: a pilot study.
1St. Luke's Philippine Movement Disorders Center, St. Luke's Medical Center, Quezon City, Philippines. evidente.virgilio@mayo.edu
Summary
Piribedil effectively treats restless legs syndrome (RLS). This pilot study showed significant symptom improvement in 85% of patients, with most reporting substantial subjective relief.
Area of Science:
- Neurology
- Pharmacology
Background:
- Restless Legs Syndrome (RLS) is a neurological disorder characterized by an irresistible urge to move the legs.
- Current treatments for RLS have limitations, necessitating exploration of alternative therapeutic agents.
Purpose of the Study:
- To evaluate the efficacy of piribedil in treating patients with Restless Legs Syndrome.
- To assess the impact of piribedil on RLS symptom severity and patient-reported outcomes.
Main Methods:
- A pilot study involving thirteen consecutive patients diagnosed with Restless Legs Syndrome.
- Patients were treated with piribedil.
- Outcomes were measured using a standardized RLS rating scale (0-10) and subjective response percentage (0-100%).
Main Results:
- Eleven out of thirteen patients (85%) experienced a reduction in their mean RLS scores.
- Subjective improvement in RLS symptoms ranged from 30% to 100%, with a mean improvement of 74.6%.
Conclusions:
- Piribedil demonstrates potential as an effective treatment for Restless Legs Syndrome.
- This pilot study provides preliminary evidence supporting the use of piribedil for RLS symptom management.